Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.83 USD
Change Today -0.33 / -3.60%
Volume 10.5K
AGRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

agile therapeutics inc (AGRX) Snapshot

Open
$8.98
Previous Close
$9.16
Day High
$9.02
Day Low
$8.73
52 Week High
04/16/15 - $13.19
52 Week Low
11/19/14 - $5.77
Market Cap
196.7M
Average Volume 10 Days
38.5K
EPS TTM
$-1.46
Shares Outstanding
22.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGILE THERAPEUTICS INC (AGRX)

Related News

No related news articles were found.

agile therapeutics inc (AGRX) Related Businessweek News

No Related Businessweek News Found

agile therapeutics inc (AGRX) Details

Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a progestin-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

15 Employees
Last Reported Date: 08/13/15
Founded in 1997

agile therapeutics inc (AGRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $522.5K
Chief Financial Officer and Vice President
Total Annual Compensation: $326.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $424.0K
Compensation as of Fiscal Year 2014.

agile therapeutics inc (AGRX) Key Developments

Agile Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Agile Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss of $8.486 million or $0.38 per basic and diluted share against net loss of $3.718 million or $0.46 per basic and diluted share for the quarter 30 June 2014. Loss from operations was $7.981 million against $3.495 million a year ago. Loss before benefit from income taxes was $8.486 million against $3.718 million a year ago. For the six months, the company reported net loss of $17.025 million or $0.78 per basic and diluted share against net loss of $2.879 million or $0.71 per basic and diluted share for the same period a year ago. Loss from operations was $14.959 million against $5.942 million a year ago. Loss before benefit from income taxes was $17.025 million against $6.532 million a year ago.

Agile Therapeutics, Inc.(NasdaqGM:AGRX) added to Russell 2000 Index

Agile Therapeutics, Inc. will be added to Russell 2000 Index

Agile Therapeutics, Inc.(NasdaqGM:AGRX) added to Russell 3000 Index

Agile Therapeutics, Inc. will be added to the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGRX:US $8.83 USD -0.33

AGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGRX.
View Industry Companies
 

Industry Analysis

AGRX

Industry Average

Valuation AGRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGILE THERAPEUTICS INC, please visit www.agiletherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.